Profiling the metabolome of uterine fluid for early detection of ovarian cancer

Cell Rep Med. 2023 Jun 20;4(6):101061. doi: 10.1016/j.xcrm.2023.101061. Epub 2023 Jun 1.

Abstract

Ovarian cancer (OC) causes high mortality in women because of ineffective biomarkers for early diagnosis. Here, we perform metabolomics analysis on an initial training set of uterine fluid from 96 gynecological patients. A seven-metabolite-marker panel consisting of vanillylmandelic acid, norepinephrine, phenylalanine, beta-alanine, tyrosine, 12-S-hydroxy-5,8,10-heptadecatrienoic acid, and crithmumdiol is established for detecting early-stage OC. The panel is further validated in an independent sample set from 123 patients, discriminating early OC from controls with an area under the curve (AUC) of 0.957 (95% confidence interval [CI], 0.894-1). Interestingly, we find elevated norepinephrine and decreased vanillylmandelic acid in most OC cells, resulting from excess 4-hydroxyestradiol that antagonizes the catabolism of norepinephrine by catechol-O-methyltransferase. Moreover, exposure to 4-hydroxyestradiol induces cellular DNA damage and genomic instability that could lead to tumorigenesis. Thus, this study not only reveals metabolic features in uterine fluid of gynecological patients but also establishes a noninvasive approach for the early diagnosis of OC.

Keywords: DNA damage; early diagnosis; metabolome; ovarian cancer; uterine fluid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Catechol O-Methyltransferase*
  • Early Detection of Cancer
  • Female
  • Humans
  • Metabolome
  • Norepinephrine
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / genetics
  • Vanilmandelic Acid

Substances

  • 4-hydroxyestradiol
  • Catechol O-Methyltransferase
  • Vanilmandelic Acid
  • Norepinephrine